A video presentation by Steve Kirsch, Executive Director of the Covid-19 Early Treatment Fund.
Note that views expressed in this presentation are those of the author and not necessarily those of TrialSite.by Steve Kirsch
Are there any risks associated with the COVID-19 vaccines currently authorized on an emergency use basis by the U.S. Food and Drug Administration (FDA)? Presently three genetic-based vaccines have been authorized via the emergency order including two mRNA-based vaccines (Moderna and Pfizer-BioNTech) as well as the adenovirus-based Johnson and Johnson product. Developed at historical speed under Operation Warp Speed, the mRNA-based technology foretells enormous implications for healthcare including the prospect of vaccines for cancer. An amazing research prowess has unfolded in response to the COVID-19 pandemic heralding profound breakthroughs that’ll benefit society for years to come. Governmental authorities have declared the vaccines both safe and effective and as TrialSIte recently reported based on a change of law that waives the need for informed consent with investigational products. Both the U.S. Centers for Disease Contr...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).